291 related articles for article (PubMed ID: 19169963)
1. Canakinumab, a fully-human mAb against IL-1beta for the potential treatment of inflammatory disorders.
Church LD; McDermott MF
Curr Opin Mol Ther; 2009 Feb; 11(1):81-9. PubMed ID: 19169963
[TBL] [Abstract][Full Text] [Related]
2. Canakinumab: a human anti-IL-1β monoclonal antibody for the treatment of cryopyrin-associated periodic syndromes.
Church LD; McDermott MF
Expert Rev Clin Immunol; 2010 Nov; 6(6):831-41. PubMed ID: 20979548
[TBL] [Abstract][Full Text] [Related]
3. Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease.
Geiler J; McDermott MF
Curr Opin Mol Ther; 2010 Dec; 12(6):755-69. PubMed ID: 21154167
[TBL] [Abstract][Full Text] [Related]
4. Canakinumab.
Dhimolea E
MAbs; 2010; 2(1):3-13. PubMed ID: 20065636
[TBL] [Abstract][Full Text] [Related]
5. Canakinumab: in patients with cryopyrin-associated periodic syndromes.
Curran MP
BioDrugs; 2012 Feb; 26(1):53-9. PubMed ID: 22168385
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1β monoclonal antibody.
Chakraborty A; Tannenbaum S; Rordorf C; Lowe PJ; Floch D; Gram H; Roy S
Clin Pharmacokinet; 2012 Jun; 51(6):e1-18. PubMed ID: 22550964
[TBL] [Abstract][Full Text] [Related]
7. Canakinumab for treatment of cryopyrin-associated periodic syndrome.
Feist E; Burmester GR
Expert Opin Biol Ther; 2010 Nov; 10(11):1631-6. PubMed ID: 20955115
[TBL] [Abstract][Full Text] [Related]
8. Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS).
Kuemmerle-Deschner JB; Ramos E; Blank N; Roesler J; Felix SD; Jung T; Stricker K; Chakraborty A; Tannenbaum S; Wright AM; Rordorf C
Arthritis Res Ther; 2011 Feb; 13(1):R34. PubMed ID: 21356079
[TBL] [Abstract][Full Text] [Related]
9. Canakinumab for the treatment of active systemic juvenile idiopathic arthritis.
Orrock JE; Ilowite NT
Expert Rev Clin Pharmacol; 2016 Aug; 9(8):1015-24. PubMed ID: 27367267
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of canakinumab in cryopyrin-associated periodic syndromes: results from a Spanish cohort.
Anton J; Calvo I; Fernández-Martin J; Gamir ML; Merino R; Jimenez-Treviño S; Sevilla B; Cabades F; Bou R; Arostegui JI
Clin Exp Rheumatol; 2015; 33(6 Suppl 94):S67-71. PubMed ID: 26243511
[TBL] [Abstract][Full Text] [Related]
11. Is IL-1 a good therapeutic target in the treatment of arthritis?
Burger D; Dayer JM; Palmer G; Gabay C
Best Pract Res Clin Rheumatol; 2006 Oct; 20(5):879-96. PubMed ID: 16980212
[TBL] [Abstract][Full Text] [Related]
12. Guidance on the use of canakinumab in patients with cryopyrin-associated periodic syndrome in Japan.
Yokota S; Nishikomori R; Takada H; Kikuchi M; Nozawa T; Kanetaka T; Kizawa T; Miyamae T; Mori M; Heike T; Hara T; Imagawa T
Mod Rheumatol; 2013 May; 23(3):425-9. PubMed ID: 23085882
[TBL] [Abstract][Full Text] [Related]
13. [Canakinumab: a promising treatment in rheumatology].
Fabreguet I; So A
Rev Med Suisse; 2012 Jan; 8(323):57-60. PubMed ID: 22303742
[TBL] [Abstract][Full Text] [Related]
14. Canakinumab for the treatment of systemic juvenile idiopathic arthritis.
Grom AA
Expert Rev Clin Immunol; 2014 Nov; 10(11):1427-35. PubMed ID: 25269376
[TBL] [Abstract][Full Text] [Related]
15. Targeting interleukin-1β in CAPS (cryopyrin-associated periodic) syndromes: what did we learn?
Koné-Paut I; Piram M
Autoimmun Rev; 2012 Nov; 12(1):77-80. PubMed ID: 22884551
[TBL] [Abstract][Full Text] [Related]
16. Targeting IL-1beta in disease; the expanding role of NLRP3 inflammasome.
Mitroulis I; Skendros P; Ritis K
Eur J Intern Med; 2010 Jun; 21(3):157-63. PubMed ID: 20493414
[TBL] [Abstract][Full Text] [Related]
17. New insights in systemic juvenile idiopathic arthritis--from pathophysiology to treatment.
Frosch M; Roth J
Rheumatology (Oxford); 2008 Feb; 47(2):121-5. PubMed ID: 17971384
[TBL] [Abstract][Full Text] [Related]
18. Canakinumab in pediatric rheumatic diseases.
Wulffraat NM; Woo P
Expert Opin Biol Ther; 2013 Apr; 13(4):615-22. PubMed ID: 23451862
[TBL] [Abstract][Full Text] [Related]
19. [CAPS treatment].
Jiménez Treviño S; Ramos Polo E
Med Clin (Barc); 2011 Jan; 136 Suppl 1():29-33. PubMed ID: 21596184
[TBL] [Abstract][Full Text] [Related]
20. At the horizon of innovative therapy in rheumatology: new biologic agents.
Finckh A; Gabay C
Curr Opin Rheumatol; 2008 May; 20(3):269-75. PubMed ID: 18388517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
